In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2792-2796

  Jacquier, H ^a,b   Marcade G ^a,b,c   Raffoux, E ^d,e   Dombret, H ^d,e   Woerther, P L ^b,f   Donay, J L ^a   Arlet, G ^g,h   Cambau, E ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h HÔPITAL TENON   (France)

Author keywords

Lactamases; Antibiotic pressure; Evolution of antibiotic resistance; Neutropenic sepsis; Third generation cephalosporins

Indexed keywords

AMIKACIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEPHALOSPORIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TINIDAZOLE; VANCOMYCIN;

ACUTE LEUKEMIA; ADULT; ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DRUG SUBSTITUTION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GENE MUTATION; GENOTYPE; HUMAN; IN VITRO SELECTION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PLASMID; POLYMERASE CHAIN REACTION;

ANTIBIOTIC PRESSURE; EVOLUTION OF ANTIBIOTIC RESISTANCE; NEUTROPENIC SEPSIS; THIRD-GENERATION CEPHALOSPORINS; Β-LACTAMASES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; MUTANT PROTEINS; PLASMIDS; RECURRENCE; SELECTION, GENETIC;

EID: 84887528616     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt278     Document Type: Article

References (17)

1. Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
2. Livermore DM. b-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
3. Canton R,Morosini MI,delaMaza O. M. et al. IRTandCMTb-lactamasesand inhibitor resistance. Clin Microbiol Infect 2008; 14 Suppl 1: 53-62.
4. Robin F, Delmas J, Brebion A.et al. TEM-158 (CMT-9), anewmemberof the CMT-type extended-spectrum b-lactamases. Antimicrob Agents Chemother 2007; 51: 4181-3.
5. Barlow M, Hall BG. Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the TEM b-lactamase. Genetics 2002; 160: 823-32.
6. Blazquez J, Morosini MI, Negri MC et al. Selection of naturally occurring extended-spectrum TEM b-lactamase variants by fluctuating b-lactam pressure. Antimicrob Agents Chemother 2000; 44: 2182-4.
7. Claeys G, De Baere T, Vaneechoutte M et al. Caz-hi, and extendedspectrum TEM b-lactamase (TEM-61), is derived from Caz-lo (TEM-11) by in vivo selection. Antimicrob Agents Chemother 1998; 42: 3328-9.
8. Dallenne C, Da Costa A, Decre D et al. Development of a set of multiplex PCR assays for the detection of genes encoding important b-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010; 65: 490-5.
9. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-8.
10. Baba T, Ara T, Hasegawa M et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2006; 2: 2006.0008.
11. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227-38.
12. Cattoir V, Lesprit P, Lascols C et al. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid. J Antimicrob Chemother 2006; 58: 1054-7.
13. Zhou XY, Bordon F, Sirot D et al. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 b-lactamase conferring resistance to b-lactamase inhibitors. Antimicrob Agents Chemother 1994; 38: 1085-9.
14. Salverda ML, De Visser JA, Barlow M. Natural evolution of TEM-1 b-lactamase: experimental reconstruction and clinical relevance. FEMS Microbiol Rev 2010; 34: 1015-36.
15. Leflon-Guibout V, Heym B, Nicolas-Chanoine M. Updated sequence information and proposed nomenclature for blaTEM genes and their promoters. Antimicrob Agents Chemother 2000; 44: 3232-4.
16. Damblon C, Raquet X, Lian LY et al. The catalytic mechanism of b-lactamases: NMR titration of an active-site lysine residue of the TEM-1 enzyme. Proc Natl Acad Sci USA 1996; 93: 1747-52.
17. Wang X, Minasov G, Shoichet BK. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 2002; 320: 85-95.